Peposertib, a DNA-PK Inhibitor, Enhances the Anti-Tumor Efficacy of Topoisomerase II Inhibitors in Triple-Negative Breast Cancer Models
International Journal of Molecular Sciences · 2024
DOI: 10.3390/ijms25105120 ↗Kurz gefasst
Fachartikel in der Zeitschrift International Journal of Molecular Sciences, 2024. Verfasst von Steffie Revia und 7 weiteren Autor:innen. Beteiligte Einrichtung: Research Unit Oncology, Merck Healthcare KGaA, Darmstadt, Germany. Hauptthemen laut MEDLINE: Drug Synergism, Topoisomerase II Inhibitors, Triple Negative Breast Neoplasms, Xenograft Model Antitumor Assays. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 25 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Merck (Germany).
Abstract (Originalsprache)
Triple-negative breast cancer (TNBC) remains the most lethal subtype of breast cancer, characterized by poor response rates to current chemotherapies and a lack of additional effective treatment options. While approximately 30% of patients respond well to anthracycline- and taxane-based standard-of-care chemotherapy regimens, the majority of patients experience limited improvements in clinical outcomes, highlighting the critical need for strategies to enhance the effectiveness of anthracycline/taxane-based chemotherapy in TNBC. In this study, we report on the potential of a DNA-PK inhibitor, peposertib, to improve the effectiveness of topoisomerase II (TOPO II) inhibitors, particularly anthracyclines, in TNBC. Our in vitro studies demonstrate the synergistic antiproliferative activity of peposertib in combination with doxorubicin, epirubicin and etoposide in multiple TNBC cell lines. Downstream analysis revealed the induction of ATM-dependent compensatory signaling and p53 pathway activation under combination treatment. These in vitro findings were substantiated by pronounced anti-tumor effects observed in mice bearing subcutaneously implanted tumors. We established a well-tolerated preclinical treatment regimen combining peposertib with pegylated liposomal doxorubicin (PLD) and demonstrated strong anti-tumor efficacy in cell-line-derived and patient-derived TNBC xenograft models in vivo. Taken together, our findings provide evidence that co-treatment with peposertib has the potential to enhance the efficacy of anthracycline/TOPO II-based chemotherapies, and it provides a promising strategy to improve treatment outcomes for TNBC patients.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Research Unit Oncology, Merck Healthcare KGaA, Darmstadt, Germany.
ORCID-Profile: Joachim Albers
Förderung
- Merck (Germany)
Zitieren
APA
Revia, S., Neumann, F., Jabs, J., Orio, F., Sirrenberg, C., Zimmermann, A., Amendt, C., & Albers, J. (2024). Peposertib, a DNA-PK Inhibitor, Enhances the Anti-Tumor Efficacy of Topoisomerase II Inhibitors in Triple-Negative Breast Cancer Models. International Journal of Molecular Sciences. https://doi.org/10.3390/ijms25105120
Vancouver
Revia S, Neumann F, Jabs J, Orio F, Sirrenberg C, Zimmermann A, et al. Peposertib, a DNA-PK Inhibitor, Enhances the Anti-Tumor Efficacy of Topoisomerase II Inhibitors in Triple-Negative Breast Cancer Models. International Journal of Molecular Sciences. 2024. doi:10.3390/ijms25105120
BibTeX
@article{Revia2024,
author = {Revia, Steffie and Neumann, Felix and Jabs, Julia and Orio, Florian and Sirrenberg, Christian and Zimmermann, Astrid and Amendt, Christiane and Albers, Joachim},
title = {Peposertib, a DNA-PK Inhibitor, Enhances the Anti-Tumor Efficacy of Topoisomerase II Inhibitors in Triple-Negative Breast Cancer Models},
journal = {International Journal of Molecular Sciences},
year = {2024},
doi = {10.3390/ijms25105120}
}
EUVIMED